Bone Biologics Corp
BBLG
View Detailed Chart
1.830USD
-0.027-1.45%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
3.29MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-1.45%
5 Days
-9.72%
1 Month
+16.56%
6 Months
-65.47%
Year to Date
-67.56%
1 Year
-70.95%
View Detailed Chart
TradingKey Stock Score of Bone Biologics Corp
Currency: USD Updated: 2025-12-19Key Insights
Bone Biologics Corp's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 237/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as , with the highest price target at 22.25.In the medium term, the stock price is expected to trend down.Despite a strong stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Bone Biologics Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
0
analysts
--
Current Rating
22.250
Target Price
+1077.25%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Bone Biologics Corp Highlights
StrengthsRisks
Bone Biologics Corporation is a clinical-stage developer of orthobiologic products for spine fusion markets. The Company is focused on bone regeneration in lumbar spinal fusion using neural epidermal growth factor-like 1 protein (NELL-1) in combination with demineralized bone matrix (DBM), a demineralized bone matrix from the Musculoskeletal Transplant Foundation (MTF) Biologics. The combination NELL-1/DBM medical device is an osteopromotive recombinant protein that provides target specific control over bone regeneration. NELL-1 in combination with DBM. NELL-1, a proprietary skeletal-specific growth factor that is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Undervalued
The company’s latest PE is -0.77, at a low 3-year percentile range.
Bone Biologics Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Bone Biologics Corp Info
Bone Biologics Corporation is a clinical-stage developer of orthobiologic products for spine fusion markets. The Company is focused on bone regeneration in lumbar spinal fusion using neural epidermal growth factor-like 1 protein (NELL-1) in combination with demineralized bone matrix (DBM), a demineralized bone matrix from the Musculoskeletal Transplant Foundation (MTF) Biologics. The combination NELL-1/DBM medical device is an osteopromotive recombinant protein that provides target specific control over bone regeneration. NELL-1 in combination with DBM. NELL-1, a proprietary skeletal-specific growth factor that is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.
Ticker SymbolBBLG
CompanyBone Biologics Corp
CEOFrelick (Jeffrey)
Websitehttps://www.bonebiologics.com/
FAQs
What is the current price of Bone Biologics Corp (BBLG)?
The current price of Bone Biologics Corp (BBLG) is 1.830.
What is the symbol of Bone Biologics Corp?
The ticker symbol of Bone Biologics Corp is BBLG.
What is the 52-week high of Bone Biologics Corp?
The 52-week high of Bone Biologics Corp is 7.740.
What is the 52-week low of Bone Biologics Corp?
The 52-week low of Bone Biologics Corp is 1.300.
What is the market capitalization of Bone Biologics Corp?
The market capitalization of Bone Biologics Corp is 3.29M.
What is the net income of Bone Biologics Corp?
The net income of Bone Biologics Corp is -7.32M.
Is Bone Biologics Corp (BBLG) currently rated as Buy, Hold, or Sell?
According to analysts, Bone Biologics Corp (BBLG) has an overall rating of --, with a price target of 22.250.
What is the Earnings Per Share (EPS TTM) of Bone Biologics Corp (BBLG)?
The Earnings Per Share (EPS TTM) of Bone Biologics Corp (BBLG) is -2.371.
Related Instruments
+1.32%
-0.88%
+1.75%
+0.83%
+0.60%
+0.38%
+0.91%
+1.03%
+2.32%
+0.60%
+0.40%
+1.97%
+1.63%
+1.21%
+0.65%
+0.66%
+2.57%
0.00%
-0.44%
+1.06%
